Skip to main content

Hybrigen, Bionomics Ink Intent to Study Breast Cancer Gene Targets

NEW YORK, Sept. 20 – Hybrigen and Bionomics Limited have signed a letter of intent to negotiate a partnership to study a pair of genes linked to breast cancer, the companies said on Thursday.

The target-discovery program will study the genes, TSG18 and BNO1, using genetic data identified and patented by Adelaide, Australia-based Bionomics, the firms said in a statement. For its part, Hybrigen, based in Dallas, will use its own proprietary proteomic technologies to discover drug targets that interact with those genes.

Both firms will share any drug targets developed from their collaboration.

TSG18 is currently being studied as a suppressor gene in certain breast cancers, while BNO1 has been shown to trigger apoptosis in certain breast cancer cells, Hybrigen and Bionomics said.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.